Guardant Health, Inc. — Form 8-K
Filed November 3, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
Guardant Health granted performance-based restricted stock units (PSUs) to co-CEOs Helmy Eltoukhy and AmirAli Talasaz: 116,353 three-year PSUs and 349,060 five-year PSUs (465,413 total target). Vesting depends on relative TSR performance versus S&P 500 peer group over 3- and 5-year performance periods starting June 1, 2026, with payouts ranging from 0% to 250% of target based on percentile achievement. The grant includes dividend equivalents and post-vesting transfer restrictions on vested shares (June 2029–May 2030 for 3-year tranche; June 2031–November 2031 for 50% of 5-year tranche).
Why this rating
At ~$6.2B market cap, 465K PSUs (~$55–75M at current valuation) represents ~1% of company value—meaningful but standard executive compensation. No business change, financial impact, or strategic shift disclosed. Routine equity grant.
See more from November 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.